Less than one in 10 patients that would benefit from obesity jabs like Wegovy have access to them, states the global health agency as it issues its inaugural recommendations on the drugs.
Given in excess of 1,000,000,000 people worldwide currently classified as obese, it is urging more widespread and fairer availability to this class of drugs.
Per forecasts, more than two billion are projected to be obese by 2030 unless action is taken.
"Our latest guidance affirms that obesity is a lifelong illness that can be managed with thorough and continuous care," said the agency's head Tedros Adhanom Ghebreyesus.
Significant expense, insufficient output, and distribution challenges are significant hurdles to widespread availability to the treatments that can aid individuals in losing substantial weight, says the agency.
Skinny Jab Shortage
Even under the present best projected outlook, the production of these medications might only reach about 100 million people – fewer than 10% of eligible patients, per the health organization.
The guideline encourages nations and manufacturers to increase access, by approaches such as voluntary licensing.
The intellectual property rights on the active ingredient – the core ingredient of a leading brand – is scheduled to end in multiple countries in 2026.
The Way Weight-Loss Injections Function
GLP-1 drugs replicate a body's own hormone to slow digestion, reduce hunger and enhance satiety so users eat less.
People usually start to lose weight after several weeks of commencing the weekly injections.
Evidence suggests users may put most of the weight back on after a year of discontinuing the medication, as their normal hunger resume.
To be above a healthy weight increases your likelihood for contracting medical conditions, like type 2 diabetes, heart disease, stroke, and specific malignancies.
Obesity impacts people in all nations and was associated with over three and a half million fatalities worldwide in 2024, per the health agency.
